Manic episodes are a defining, frequent and dramatically disabling occurrence in the course of Bipolar Disorder type I. Current pharmacotherapy of mania lists a good number of agents, but differences in efficacy and safety profiles among these agents must be considered in order to tailor personalized therapies, especially when the long-term course of the illness is considered. There is wide room and need to ameliorate current pharmacological approaches to mania, but ongoing pharmacological research on the topic is scant. In this work we try to critically assess clinical factors and patients’ characteristics that may influence the treatment choice for manic episodes. In addition, we conduct a narrative review on experimental pharmacology of bipolar mania and psychotic disorders, presenting a critical overview on agents which could represent treatment alternatives for a manic episode in the next future. Results show limited novel or ongoing research on agents acting as mood stabilizers (Ebselen, Valnoctamide and Epalrestat did not reach statistical significance in demonstrating antimanic efficacy). As for the emerging experimental antipsychotic, some of them (including KarXT, SEP-363856, RO6889450, ALKS3831) have demonstrated good antipsychotic efficacy and a favorable safety profile, but little is known about their use in patients with bipolar disorder and specifically designed trials are needed. Lastly, some benefits for the treatment of mania could be expected to come in the next future from non-mood stabilizers/non-antipsychotic agents (especially PKC inhibitors like Endoxifen): long-term trials are needed to confirm positive results in terms of long-term efficacy and safety.

Translational Psychiatry (2022)12:169; https://doi.org/10.1038/s41398-022-01928-8

INTRODUCTION
Bipolar Disorders (BDs) are a group of severe mood disorders with a chronic and recurrent course, characterized by periods of euthymia alternated with manic/hypomanic, depressive with or without the presence of mixed features and mixed episodes [1]. BDs rank as the 17th leading source of disability among all diseases worldwide with the highest suicide rate among all psychiatric conditions, being 20–30 times higher than in the general population [1]. Within BDs, manic episodes (MEs) affect overall more than 1% of the general population [2]. The presence of a manic episode is the required criterion needed for the diagnosis of BD type I (BD-I).

The 5th and last edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) has made changes to the “criterion A” for a ME, which now requires a distinct period of abnormally and persistently elevated, expansive, or irritable mood and abnormally and persistently increased activity or energy present most of the day, almost every day for minimum 1 week (or less if patient requires hospitalization) [3]. According to the DSM-5 definition, a ME must be accompanied by marked impairment in psychosocial functioning, require hospitalization, and/or involve psychotic symptoms. Another difference between DSM-5 and its prior editions is that a diagnosis of BD-I can now be made in patients in whom the ME emerges while being treated (i.e., with medication or ECT) for major depression, when a fully syndromic ME persists beyond the expectable effect of the treatment. Moreover, in DSM-5 the diagnosis of “mixed episode” no longer exists, and has been replaced with the more dimensional “with mixed features” specifier that can be applied to mania or hypomania. The DSM-5 included other specifiers that can accompany a manic episode, such as anxious distress, rapid cycling, mood-congruent or mood-incongruent psychotic features, catatonia, peripartum onset, and seasonal pattern. As for latest version of the International Classification of Diseases (ICD-11), which from 2022 should be in worldwide use, the definition of a ME is now almost identical with the DSM-5 as regards entry criteria, duration, hospitalization, and the presence or absence of psychotic features and impairment in social and occupational functioning, although with some formal and methodological dissimilarities (e.g. ICD-11’s descriptions of the “essential features” of mood episodes are not presented as equivalents of strict diagnostic criteria and symptom counts or duration cut-offs are generally absent) [4–6].

From a clinical point of view, one first interesting point to be remarked is that a ME actually represents an heterogenous entity. In fact, the DSM-5 recognizes up to 7 clinical specifiers for a ME and each of these could require a different therapeutic approach in terms of prevention, early intervention, pharmacotherapy, psychotherapy, psychoeducation and rehabilitation.

Another important point to consider is that a ME needs to be understood and treated not in a “cross-sectional” way, but as a
phenomenon included in the complex and long-lasting course of bipolar illness. As a consequence, the treatment of the acute manic phase should already consider the maintenance treatment and course specifiers, such as the number of episodes, predominant polarity, the presence of rapid cycling, the risk of counterpolar switch [7], making the pharmacological treatment a complex choice. Predominant polarity (PP) is a course specifier concept aimed at identifying the presence of a predominant affective pole of illness within the same patient across its illness course [8]. Data on manic PP in the course of BD-I is conflicting since it ranges from 11.5 to 45.7% across studies [9, 10] mainly due to variation of temporal criteria used for defining PP. Strictly connected with PP is the concept of Polarity Index (PI), a metric used to orient pharmacotherapy in BD on the basis of PP which will be discussed in the next section.

Other clinical aspects that should be considered when treating a ME include the management of psychomotor agitation; the differences in the manic symptoms presentation in order to personalize treatment for a specific patient as much as possible (precision psychiatry); the need for using monotherapy versus combination therapy; the presence of mood incongruent psychotic symptoms which will require a more complex treatment; the importance of addressing compliance issues and the possibility of choosing long-acting formulations. Lastly, safety/tolerability issues in the short and long-term treatment, the presence of psychiatric/medical comorbidities and the need for a functional recovery complete this complex scenario [7, 11].

As for the biological bases, multiple factors interact in the complex equation of the pathophysiology of a ME, such as neuro-hormonal pathways, neurotransmission, signal transduction, regulation of gene expression, oxidative stress, neuroplasticity, changes in the immune system, psychosocial, developmental and environmental stress events and the severity of the episode [12]. Overall, these factors could represent specific pharmacological targets.

The aim of this paper is to critically assess clinical factors and patients’ characteristics that may influence the treatment choice in mania, as well as review the current, evidence-based pharmacological treatments for mania. Finally, we will discuss emerging and experimental pharmacological options which could represent useful alternative in treating a manic episode in the near future.

METHOD
We conducted a narrative, non-systematic review of literature about (i) current pharmacotherapy of bipolar mania, (ii) novel and experimental pharmacotherapy of bipolar mania, and (iii) novel and experimental pharmacotherapy of psychotic disorders. For this purpose, in May 2021 we conducted a series of targeted literature searches in PubMed, clinicaltrials.gov and clinicaltrials-register.eu. Key words for the search—pharmacological treatment/drugs therapy/pharmacotherapy of bipolar mania, psychotic disorders and schizophrenia—were identified by our team of experts. The need for including key words related to psychotic disorders was motivated by both: (a) many current pharmacological approaches to mania sharing indication for psychotic disorders and (b) the paucity of ongoing experimental pharmacology studies specifically dedicated to mania and the consequent need for looking at the richer field of psychotic disorders experimental pharmacology, wherefrom many drugs have come in the last decades which are currently used for treating MEs.

Only articles written in English language and published in the last ten years (May 2011–May 2021) were searched. All abstracts were checked by the authors and all kinds of study design were critically taken into consideration. Also, some papers identified in the reference list of the papers from the original search were considered. The results were then synthesized and incorporated with clinical experience of the authors.

RESULTS
Existing approaches to the treatment of mania
The existing approaches for the treatment of MEs are summarized and categorized in Table 1. A tentative treatment algorithm can be found in a recently published work from our same research group [7].

Lithium
Lithium still represents the cornerstone of BD treatment. Actually, it ranks as a first-line option for Mania in most current clinical guidelines, both as monotherapy and in combination [7, 11, 13]. Moreover, together with quetiapine, lithium is the only first-line agent which also presents a level 1 evidence of efficacy for prevention of both manic and depressive episodes in the maintenance treatment [13]. Moreover, lithium is usually considered to have a better tolerability profile than quetiapine, especially in the short-term, due to its lack of sedative, hypotensive and direct neurological side-effects [11, 14]. Widely recognized pros of lithium therapy are also its intrinsic antisuicidal and neuro-protective properties [7, 11]. Conversely, the oftencited cons of lithium therapy include a relatively narrow therapeutic index, and the long-term side effects especially on kidney and thyroid function, thus requiring periodic monitoring and blood testing. In terms of a personalized approach, several authors agree in identifying those patients with clinical features that are indicative of a good response to lithium treatment, such as a more classic grandiose or euphoric mania, with fewer prior episodes, with a mania-depression-euthymia course, and those with a family history of BD [7, 11].

Valproic acid (VPA) and carbamazepine (CBZ)
Both these anticonvulsants have been approved by regulatory agencies for the treatment of MEs, having a level 1 evidence of efficacy for Mania according to the latest guidelines of the Canadian Network for Mood and Anxiety Treatments and International Society for Bipolar Disorders (CANMAT/ISBD) [11]. Nonetheless, in terms of recommendation grade, only VPA is listed as a first-line agent, mainly because of the safety and tolerability issues associated with the treatment with CBZ. Regarding the clinical indications in mania, VPA and to a less extent CBZ, should be prescribed when lithium is not recommended, such as in previous lithium non-response, renal failure, severe dermatological disease, severe gastrointestinal intolerance, cardiovascular insufficiency, Addison’s disease or/and untreated hypothyroidism. Moreover, they could be indicated in BD patients with predominately irritable or dysphoric mood, comorbid substance abuse, multiple prior episodes of illness and/or a history of head trauma [7, 15–19] Of note, due to serious teratogenic effects, both VPA and CBZ are contraindicated in women of childbearing age [20, 21].

Second generation antipsychotics (SGAs)
The majority of SGAs, such as quetiapine, asenapine, olanzapine, ziprasidone, aripiprazole, risperidone, and cariprazine are also approved by regulatory agencies in United States and Europe as monotherapy for the treatment of mania. With the exception of ziprasidone, all the above-mentioned SGAs are recommended as first-line option for MEs with a level 1 evidence and comparable efficacy to lithium and anticonvulsants. Only the role of olanzapine as a first-line treatment option is controversial, mainly because of long-term safety and tolerability metabolic issues [13]. Despite this, clinical literature and guidelines often agree on the point that SGAs’ indication as monotherapy in MEs only - and partially -applies if the diagnostic possibility of schizoaffective disorder with manic symptoms is considered [7, 11]. On the other hand, the use of SGAs in combination with lithium or divalproex can be actually considered as first-line in MEs with higher severity index, whenever a response is needed faster, in patients with mood-
Table 1. Current first-line and second-line options for the treatment of acute mania.

| Level of evidence and recommended dosages<sup>a</sup> | Safety and tolerability concerns |
|--------------------------------|--------------------------------|
| **Acute mania** | **Recommended dose (mg/day)<sup>b</sup>** | **Maintenance after mania** | **Acute** | **Maintenance** |
| **Prevention of mania** | **Prevention of depression** | **Safety concerns** | **Tolerability concerns** | **Safety concerns** | **Tolerability concerns** |
| First-line treatments<sup>c</sup> | | | | | |
| Lithium<sup>d</sup> | 600-1200 (serum level 0.6-1.0 mmol/l or mEq/l) | | | | |
| Divalproex<sup>e</sup> | 1200-3000 (serum level 75-150 mg/l) | | | | |
| Aripiprazole | 15-30 | | | | |
| Paliperidone | 6-12 | | | | |
| Risperidone | 2-6 | | | | |
| Asenapine | 10-20 | | | | |
| Olanzapine | 10-20 | | | | |
| Quetiapine | 400-800 | | | | |
| Cariprazine | 3-12 | | | | |
| Aripiprazole + Li/DVP<sup>d</sup> | * | | | | |
| Risperidone + Li/DVP<sup>d</sup> | * | | | | |
| Asenapine + Li/DVP<sup>d</sup> | * | | | | |
| Olanzapine + Li/DVP<sup>d</sup> | * | | | | |
| Quetiapine + Li/DVP<sup>d</sup> | * | | | | |
| Second-line treatments<sup>f</sup> | | | | | |
| Carbamazepine<sup>e</sup> | 600-1200 (serum level 4-15 mg/l) | | | | |
| Haloperidol | 5-20 | | | | |
| Ziprasidone | 80-120 | | | | |
| Lithium + DVP<sup>g</sup> | * | | | | |
| ECT | | | | | |

Abbreviations: DVP: divalproex; ECT: electroconvulsive therapy; Li: lithium.

Divalproex, electroconvulsive therapy, Li lithium.

<sup>a</sup>Strength of evidence base for the efficacy of agents used to treat mania: level 1 evidence: meta-analysis with narrow confidence interval or replicated double-blind (DB), randomized controlled trial (RCT) placebo or active-controlled (n ≥ 30 in each active treatment arm); level 2 evidence: meta-analysis with wide confidence interval or one DB RCT, placebo or active-controlled (n ≥ 30 in each active treatment arm); level 3 evidence: at least one DB RCT placebo or active-controlled (n = 10–29 in each active treatment arm) or health system administrative data; level 4 evidence: uncontrolled trial, anecdotal reports or expert opinion; level 1 negative evidence; level 2 negative evidence; level 3 negative evidence; level 4 negative evidence; no data; limited or minor impact on treatment selection; moderate impact on treatment selection; significant impact on treatment selection.

<sup>b</sup>Doses are reported as per studies.

<sup>c</sup>Treatments are listed by drug class: mood stabilizers, antipsychotics and combination treatments. In each subsection, the recommendations follow a hierarchical order (i.e. lithium before divalproex, aripiprazole before paliperidone, etc). Although monotherapies are listed above combination therapies in the hierarchy, polytherapy may be indicated as the best choice in patients with severe manic episodes and/or a previous history of partial response to monotherapy.

<sup>d</sup>Divalproex and carbamazepine should be avoided in women of childbearing age.

<sup>e</sup>Same recommended doses as monotherapy for each individual treatment.

incongruent psychotic or mixed features and/or in those with a previous history of partial response to monotherapy (this is valid except for paliperidone and ziprasidone, whose trials as adjunctive therapies to lithium/divalproex showed lack of efficacy, maybe because of trials’ methodological problems) [11]. Additionally, combination treatment should be considered if no sufficient clinical response is observed after 1–2 weeks with therapeutic doses of a first-line antimanic agent, after dose-optimizing has been performed, non-adherence issues identified and addressed and consideration given to possible substance abuse [11]. Second and third-line choices should be taken in consideration only after multiple trials with adequate dosage of first-line options.

When poor adherence is identified as one of the main reasons for partial or no-response, a long-acting (LA) formulation of SGAs should be offered and, whenever possible, discussed with patients and/or their caregivers as a treatment option. Among SGAs, only Aripiprazole LA formulation is currently labelled as a treatment option for maintenance therapy in BD both in the United States and in Europe, since it has been found effective in delaying manic recurrences without inducing depressive episodes [22]. Other LA SGAs have demonstrated efficacy in treating and preventing manic episodes, with a better level of evidence for risperidone LA, which is in fact approved for maintenance therapy in BD-I in the United States but not in Europe. Nonetheless, neither risperidone LA nor paliperidone LA proved effective in the treatment and prevention of depressive episodes or depressive recurrences in BD, so their use as first-line treatment should be limited to BD patients with manic predominant polarity [23–26]. More broadly, the polarity index of a drug—a RCT-based metric to guide maintenance treatment choice in BD [27]—can be useful to appraise clinical differences among SGAs and tailor personalized therapies [7, 27].

Regarding the use of SGAs as maintenance treatment, it is important to remark that not all SGAs share the same level of evidence for efficacy as maintenance treatment, with only quetiapine classified as level 1 and many in need of further studies to assess efficacy in the long-term [13] (see Table 1). Lastly, it seems important to remark that SGAs are generally considered...
to represent an advance compared to First Generation Anti-psychotics (FGAs), not much on the efficacy side since they share similar level of evidence on this point, but rather for their safety/tolerability profile, avoiding the severe neurological side effects of FGAs, both in the short and the long term. Nevertheless, the use of SGAs is still loaded with important side effects, which somehow shifted on the metabolic side, i.e. weight gain and metabolic syndrome above all, especially for agents like olanzapine. Moreover, some of the old tolerability problems of FGAs, i.e. hyperprolactinemia for risperidone and paliperidone or sedation for quetiapine, whether attenuated are also displayed by SGAs [28]. Thus, it is important to keep in mind that there is extensive evidence (see Table 1), but the risk for counterpolar depressive psychotics (FGAs), not much on the efficacy side, but rather for their safety/tolerability profile, avoids the severe neurological side effects of FGAs, both in the short and the long term. Nevertheless, the use of SGAs is still loaded with important side effects, which somehow shifted on the metabolic side, i.e. weight gain and metabolic syndrome above all, especially for agents like olanzapine. Moreover, some of the old tolerability problems of FGAs, i.e. hyperprolactinemia for risperidone and paliperidone or sedation for quetiapine, whether attenuated are also displayed by SGAs [28]. Thus, it is important to keep in mind that there is extensive evidence on this point, but rather for their safety/tolerability profile, especially when considering long-term use after treating an acute ME.

Among FGAs, haloperidol presents a long-known efficacy in the treatment of acute mania and it is still classified as level 1 evidence (see Table 1), but the risk for counterpolar depressive switch and its poor safety/tolerability profile suggests its use as a second-line option or use in special populations, such as manic pregnant women due to its long-known reproductive safety [7].

In the case of a refractory ME, a pharmacogenetic study of cytochrome P450 enzymes (especially 2D6 and 3A4) could be indicated to exclude the eventualty of rapid/ultra-rapid metabolizers. Finally, Clozapine [29] and Electro-Convulsive Therapy (ECT) [30–32] are the main treatment options to be considered in refractory ME, when all the above-mentioned options are not effective.

Indications for current treatment options in special populations (children and adolescents, older-age, childbearing and breastfeeding women) can be found in all major guidelines and recent works on this topic [7, 11, 13].

**EMERGING APPROACHES TO THE TREATMENT OF MANIA**

We divided this chapter into four sub-sections: (i) experimental mood-stabilizers (MSs), (ii) re-labelling antipsychotics (APs), (iii) experimental APs and (iv) non-MS/non-AP agents. Emerging approaches for the treatment of Mania are summarized and categorized in Table 2.

As mentioned above, regarding emerging and experimental approaches to mania three main issues should be considered: (a) experimental research is poorly dedicated specifically to the psychopharmacology of manic episodes; (b) the consequent—whether motivated—need for looking at the field of experimental psychopharmacology in Schizophrenia in order to bridge the gap in the experimental research of psychopharmacology of manic episodes and (c) in both BD and Schizophrenia, current research is focused more on overcoming safety and tolerability side effects of existing drugs rather than potentiating their efficacy profiles.

**Experimental mood stabilizers**

Three experimental MSs are listed in Table 2.

Ebselon: this compound has been chosen as an experimental MS for its strong activity as inositol monophosphatase (IMPase) inhibitor, one of the putative pharmacological targets of lithium [33]. In a recent phase IIa, double-blind, placebo-controlled, add-on randomized clinical trial (RCT) with in/outpatients suffering from mania or hypomania, Ebselon was not statistically superior to placebo in reducing manic symptoms after 3 weeks of treatment, even though descriptive data indicated a tendency towards superiority [34]. The two groups did not differ significantly in terms of adverse effects. The authors concluded that Ebselon deserves further research in which concomitant psychotropic treatment is better controlled [34].

Valnoctamide: this divalproex derivative with demonstrated IMPase inhibition activity but no demonstrated activity in inhibiting voltage-gated sodium channels, was tested as monotherapy for acute mania and compared to placebo and risperidone in one RCT [35]. Valnoctamide was supposed to have a better reproductive tolerability profile than Divalproex since it showed decreased risk for congenital abnormalities in animals. The results of the RCT showed lack of efficacy for this agent. Investigators hypothesized that the lack of efficacy could be due to the above-mentioned pharmacodynamic differences between Valnoctamide and Divalproex [35].

Elsicarbazepine: is an oxcarbazepine-like anticonvulsant agent, approved in 2009 for treatment of partial onset seizures. In a multicenter, double-blind RCT, Elsicarbazepine was tested in patients with acute mania in search of an effective alternative to MSs. As in the two precedent cases, results showed lack of efficacy in primary outcomes [36].

**Re-labelling antipsychotics**

Three agents are listed in Table 2.

Brexpiprazole is a dopamine D2 receptor partial agonist and serotonergic 5HT1A partial agonist/5HT2A antagonist, is already indicated as monotherapy for Schizophrenia and as adjunctive treatment to antidepressants for Major Depressive Disorder. In pre-approval trials, Brexpiprazole showed signs of a better safety/tolerability profile than other drugs of its same class (namely aripiprazole, cariprazine) so it was recently tested as treatment for acute mania in two double-blind placebo-controlled and one open-label long-term RCT [37]. The results of the trials indicated a lack of statistically significant difference in terms of efficacy between brexpiprazole and placebo. Possible explanations for this failure may include slow titration/ modest dose schedules and samples’ heterogeneity, especially with respect to psychopathological features (above all insight) and standards of care (hospitalization vs outpatient treatment) [37].

Iloperidone is a dopamine/serotonin receptor antagonist (D2, 5HT2A) approved in 2009 by the Food and Drug Administration (FDA) for use in Schizophrenia. However, iloperidone did not receive the marketing authorization by the European Medicines Agency (EMA) in 2018, mainly because of worries about QTc prolongation risk [https://www.ema.europa.eu/en/documents/assessment-report/fanaptum-epar-refusal-public-assessment-report_en.pdf]. Nonetheless, Iloperidone is considered to show a good safety/tolerability profile in comparison with other antipsychotics, especially on the metabolic and neurological sides [38]. It is currently being tested in patients with acute mania in a multicenter double-blind placebo-controlled RCT, expected to be completed in May 2023 [39].

Cariprazine is a dopamine D3 > D2 partial agonist, already approved by the FDA for the treatment of bipolar mania and bipolar depression and by the EMA for the treatment of schizophrenia. It is currently under study in a placebo-controlled RCT to evaluate its long-term safety/tolerability profile and its efficacy in preventing relapses of both mania and depression in BD [40]. In case of yielding positive results, cariprazine could improve its evidence base as a treatment for all phases of BD.

**Experimental antipsychotics**

ALKS3831 is a combination of olanzapine plus samidorphan, a new chemical entity that acts as a μ-opioid modulator. ALKS3831 is currently under development in phase III trials to test its efficacy and safety in patients with Schizophrenia and BD [41]. The adjunct of samidorphan was primarily intended to mitigate weight gain, a well-known side effect of olanzapine, while useful secondary outcomes of this combination might include reduced craving for alcohol and mood regulation via the opioid system [42]. In a recent phase III trial in patients with schizophrenia, a combination of different doses of olanzapine/samidorphan was double-blindly compared to olanzapine alone. While retaining a similar antipsychotic efficacy to olanzapine, the combined treatment proved to be effective in reducing olanzapine-induced weight-gain [43].
| Agent                      | Mechanism of action | Health condition | Study Phase | Status | Duration | N   | Study design and drug doses                                                                 | Primary outcomes | Results                                                                 | Adverse Effects | Reference  |
|----------------------------|---------------------|------------------|-------------|--------|----------|-----|------------------------------------------------------------------------------------------------|-----------------|----------------------------------------------------------------------|-----------------|------------|
| Ebselen                    | IMPase inhibitor    | Mania or Hypomania | RCT         | II     | Completed| 3 weeks 68 | Add-on to TAU, in/outpatients, placebo-controlled, Ebselen 600 mg bid | YMRS            | No statistical difference with placebo in YMRS                      | Comparable to placebo | Sharpley et al. [34] |
| Valnoctamide               | IMPase inhibitor    | Mania            | RCT         | II     | Completed| 3 weeks 173 | Monotherapy, three-armed (71=valnoctamide, 32=risperidone, 70=placebo) Valnoctamide 1500 mg/d | YMRS            | No statistical difference with placebo in YMRS                      | Comparable to placebo | Weiser et al. [35] |
| Eslicarbazepine            | Voltage-dependent sodium channel inhibitor | Mania            | RCT         | II     | Completed| 3 weeks 160 | Monotherapy, placebo-controlled, parallel group, dose titration Eslicarbazepine up to 2400 mg/d | YMRS            | No statistical difference with placebo in YMRS                      | Slightly superior to placebo (dizziness, headache, nausea) | Grunze et al. [36] |
| Brexpiprazole              | D2 par ago          | Mania            | RCT         | III    | Completed| 3 weeks 322 | Monotherapy, placebo-controlled | YMRS            | No statistical difference with placebo in YMRS                      | Akathisia       | Vieta et al. [37] |
| Iloperidone                | D2 antago SHT2A antago | Mania            | RCT         | III    | Ongoing (ends May 2023) | 4 weeks 400 (est) | Monotherapy, placebo-controlled | YMRS            | Pending                                                                 | Pending         | NCT04819776 [38] |
| Cariprazine                | D2/D3 par ago       | Maintenance BD   | RCT         | III    | Ongoing (ends July 2023) | 52 weeks 822 | Cariprazine: 1.5–3 mg/d | Pending            | Pending                                                                 | Pending         | NCT03573297 [39] |
| ALKS3831 (OLZ + SAM)       | OLZ: D2 antago SHT2A antago | OLZ: D2 antago SHT2A antago | RCT         | III    | Completed| 4 weeks 352 | Monotherapy, olanzapine and placebo-controlled, OLZ = 10–20 mg; SAM = 10 mg | PANSS-tot, CGI-S | OLZ + SAM > placebo in PANSS-tot and CGI-S | Weight gain, dry mouth, somnolence, anxiety, headache | Potkin, Kunovac, Silverman et al. [100] |
| SEP-363856 (TAAR1 ago)     | Xanomeline: Cholinergic M2 ago Trospium: peripheral M antagonist | Acute Schizophrenia | RCT         | III    | Completed| 5 weeks 182 | Monotherapy, placebo-controlled, Xanomeline up to 125 mg bid; Trospium up to 30 mg bid | PANSS-tot | KarXT > Placebo in PANSS-tot | constipation, dry mouth, dysphoria, vomiting | Biannan et al. [44] |
| SEP-363856 (TAAR1 ago)     | Xanomeline: Cholinergic M2 ago Trospium: peripheral M antagonist | Acute Schizophrenia | RCT         | III    | Completed| 4 weeks 245 | Monotherapy, placebo-controlled, SEP-363856: 50–75 mg/d | PANSS-tot | SEP-363856 > Placebo in PANSS-tot | Somnolence and GI symptoms | Koblan et al. [46] |
| SEP-363856 (TAAR1 ago)     | Xanomeline: Cholinergic M2 ago Trospium: peripheral M antagonist | Acute Schizophrenia | RCT         | III    | Completed| 4 weeks 245 | Monotherapy, placebo-controlled, SEP-363856: 50–75 mg/d | PANSS-tot | SEP-363856 > Placebo in PANSS-tot | Somnolence and GI symptoms | Koblan et al. [46] |
| SEP-363856 (TAAR1 ago)     | Xanomeline: Cholinergic M2 ago Trospium: peripheral M antagonist | Acute Schizophrenia | RCT         | III    | Completed| 5 weeks 182 | Monotherapy, placebo-controlled, SEP-363856: 50–75 mg/d | PANSS-tot | SEP-363856 > Placebo in PANSS-tot | Somnolence and GI symptoms | Koblan et al. [46] |
| Agent | Mechanism of action | Health condition | Study | Phase | Status | Duration | N | Study design and drug doses | Primary outcomes | Results | Adverse Effects | Reference |
|-------|---------------------|------------------|-------|-------|--------|----------|---|-----------------------------|----------------|---------|-----------------|-----------|
| RO6889450 (Ralmitant) | TAAR1 par ago | Acute Schizophrenia or Schizoaffective Disorder | RCT | II | Ongoing (ends Apr 2023) | 4 weeks | 308 (est) | Monotherapy, placebo and risperidone-controlled Ralmitant: 45–150 mg/d Risperidone: 4 mg/d | PANSS-tot | Pending | Pending | NCT04512066 (49) |
| Lumateperone | SHT2A antago, D2 par ago, glutamate (NMDA GluN2B) enhancer | Acute Schizophrenia | RCT | II | Completed | 4 weeks | 311 | Monotherapy, placebo and risperidone-controlled; Lumateperone: 42–84 mg/d Risperidone: 4 mg/d | PANSS-tot | Only lumateperone 42 mg/day placebo in ↓ PANSS-tot | Headache, somnolence, dizziness | Greenwood et al. [101] |
| Brilaroxazine | Serotonin-dopamine modulator | Acute Schizophrenia | RCT | II | Completed | 4 weeks | 234 | Monotherapy, placebo and aripiprazole-controlled Brilaroxazine: 15, 30, 50 mg/d Aripiprazole: 15 mg | PANSS-tot | BrilaroxazinePlacebo in ↓ PANSS-tot for 15 mg and 50 mg/d | Insomnia, agitation | Cantillon et al. [55] |
| F17464 | D3 antago | Acute Schizophrenia | RCT | II | Completed | 6 weeks | 134 | Monotherapy, placebo-controlled F17464: 20 mg bid | F17464 > Placebo in ↓ PANSS-tot | Insomnia, agitation, increased triglycerides | Bitter et al. [103] |
| AVN-211 | SHT6 antago | Chronic Schizophrenia | RCT | II | Completed | 4 weeks | 42 | Add-on to SOC, placebo-controlled AVN-211: 0.05–0.2/kg/d | PANSS, CGI-S, WAIS | AVN-211 > Placebo in ↓ PANSS-tot | Insomnia, agitation, increased triglycerides | Capuzzo et al. [104] |
| Cannabidiol (CBD) | CB1 par ago | Chronic Schizophrenia | RCT | II | Completed | 6 weeks | 88 | Add-on to SOC, placebo-controlled CBD: 1000 mg/d | PANSS, CGI-S, CGI-GAF, BACS | CBD > placebo in ↓ PANSS-positive score, CGI-S and WAIS scores | Comparable to placebo | McGuire et al. [105] |
| Sodium Nitroprusside (SN) | Nitric Oxide donor | Acute Schizophrenia | RCT | n/a | Completed | 5 weeks | 2 | Monotherapy, CBD: 600–1200 mg/d | YMRS | No evidence of efficacy | Well tolerated | Zuardi et al. [60] |
| Acute Schizophrenia | RCT | n/a | Completed | 4 weeks | 42 | Same as above | PANSS | No statistical significance | Well tolerated | Wang et al. [64] |
| Acute Schizophrenia | RCT | n/a | Completed | 4 weeks | 20 | Same as above | BPRS-18 PANSS | No statistical significance | Well tolerated | Stone et al. [63] |
| Acute Schizophrenia | RCT | n/a | Completed | 2 weeks | 52 | Same as above | PANSS | No statistical significance | Well tolerated | Brown et al. [66] |
| MK-8189 | PDE10A inhibitor | Acute Schizophrenia | RCT | II | Completed | 4 weeks | 224 | Monotherapy, placebo and risperidone-controlled; MK-8189 up to 12 mg/d Risperidone up to 6 mg | PANSS | No statistical difference with placebo in ↓ PANSS-tot | n/a | NCT03055338 (66) |
| Acute Schizophrenia | RCT | II | Ongoing (ends July 2022) | 6 weeks | 576 | MK-8189 up to 24 mg/d Risperidone up to 6 mg | PANSS | Pending | Pending | NCT04624243 (67) |
| BI 409306 | PDE9A inhibitor | Attenuated Psychosis Syndrome | RCT | II | Completed | 52 weeks | 50 | Monotherapy, placebo-controlled, dose n/a | Time to remission | Pending | Pending | NCT03230097 (69) |
| Pimavanserin (PIM) | SHT2A inverse ago | Acute Schizophrenia | RCT | III | Completed | 6 weeks | 423 | Add-on to risperidone or haloperidol, placebo-controlled | PANSS | PIM + risperidone2mg equally efficacious as | Headache, Somnolence, Insomnia | Meltzer et al. [70] |
| Agent | Mechanism of action | Health condition | Study | Phase | Status | Duration | N  | Study design and drug doses | Primary outcomes | Results | Adverse Effects | Reference |
|-------|---------------------|-----------------|-------|-------|--------|----------|----|-----------------------------|----------------|---------|------------------|-----------|
| Treatment-resistant Schizophrenia | RCT | III | Completed | 6 weeks | 396 | Add-on to SOC, placebo-controlled | PANSS | No statistical difference with placebo in PANSS-tot | Well tolerated | NCT02970292 [71] |
| Negative Symptoms in Schizophrenia | RCT | III | Ongoing (ends Mar 2023) | 26 weeks | 426 | Add-on to SOC, placebo-controlled | NSA-16 | Pending | Pending | NCT04531982 [106] |
| Evenamide | Glutamate modulator and voltage-gated sodium channel blocker | RCT | III | Completed | 4 weeks | 89 | Add-on to risperidone or aripiprazole, placebo-controlled | PANSS | Evenamide/placebo in PANSS-tot | Well tolerated | Anand et al. [74] |
| Acute Schizophrenia | RCT | III | Completed | 4 weeks | 138 | Add-on to SOC, placebo-controlled | PANSS | Pending | Pending | NCT04461119 [75] |
| Experimental non-mood-stabilizer/non-antipsychotic agents | | | | | | | | | | |
| Endoxifen | PKC inhibitor | Mania or mixed state | RCT | III | Completed | 3 weeks | 84 | Monotherapy, divalproex-controlled Endoxifen: 4-8 mg/d | YMRS | Endoxifen faster than divalproex in ↓ YMRS | Well tolerated as compared to divalproex | Ahmad et al. [78] |
| Mania | RCT | III | Completed | 3 weeks | 228 | Monotherapy, divalproex-controlled Endoxifen: 8 mg/d | YMRS | Endoxifen faster than divalproex in ↓ YMRS | Headache, insomnia, vomiting | Ahmad et al. [79] |
| Mania | RCT | III | Completed (ended May 2021) | 3 weeks | 124 | Monotherapy, placebo-controlled Endoxifen: 8 mg/d | YMRS | Pending | Pending | NCT04315792 [107] |
|Tamoxifen (TMX) | PKC inhibitor | Mania or Hypomania | PS | n/a | Completed | 4 weeks | 13 | Monotherapy, placebo-controlled TMX: 40 mg/d | CARS-M | TMX > placebo in ↓ CARS-M | n/a | Kulkarni et al. [108] |
| Mania or Mixed State | RCT | III | Completed | 3 weeks | 16 | Monotherapy, placebo-controlled TMX: 20-160 mg/d | YMRS | TMX > placebo in ↓ YMRS | Loss of appetite | Zaate et al. [109] |
| Mania or Mixed State | RCT | III | Completed | 3 weeks | 50 | Monotherapy, placebo-controlled TMX: 80 mg/d | YMRS | TMX > placebo in ↓ YMRS | Comparable to placebo | Yildiz et al. [110] |
| Mania | RCT | III | Completed | 6 weeks | 40 | Add-on to lithium, placebo-controlled TMX: 80 mg/d | YMRS, PANSS | TMX > placebo in ↓ YMRS and PANSS | Fatigue | Amroshahi et al. [111] |
| Mania | RCT | III | Completed | 4 weeks | 51 | Add-on to SOC, placebo-controlled | CARS-M | No statistical difference | Comparable to placebo | Kulkarni et al. [112] |
| Celecoxib | COX-2 inhibitor | Mania without psychotic symptoms | RCT | III | Completed | 6 weeks | 46 | Add-on to divalproex, placebo-controlled Celecoxib: 400 mg/d | YMRS | Celecoxib-placebo in ↓ YMRS | Comparable to placebo | Arabzadeh et al. [81] |
| Mania without psychotic symptoms | RCT | III | Completed | 8 weeks | 40 | Add-on to lithium, risperidone, placebo-controlled | YMRS | Celecoxib-placebo in ↓ YMRS | Comparable to placebo | Musavi et al. [82] |
| N-acetylcisteine (NAC) | Multi-target molecule with anti-oxidant properties | Mania or Hypomania | RCT (post-hoc analysis) | III | Completed | 24 weeks | 15 | Add-on to TAU, placebo-controlled NAC: 1000 mg bd | YMRS | NAC > placebo in ↓ YMRS | Comparable to placebo | Magailhães et al. [83] |
| Omega-3 polysaturated fatty acids | Arachidonic acid competitor | Mania | RCT | III | Completed | 4 weeks | 14 | Add-on to divalproex, placebo-controlled Omega-3: EPA 440 mg + DHA 240 | YMRS, PANSS | No statistical difference | Comparable to placebo | Chiu et al. [84] |
| Probiotics (Lactobacillus) | Regulation of gut-microbiota | Remitted Mania | RCT | III | Completed | 24 weeks | 66 | Probiotics > placebo in rehospitalization index | Comparable to placebo | Dickerson et al. [85] |
### Table 2. Mechanisms and effects of new agents

| Agent | Mechanism of action | Health condition | Study design and drug doses | Results | Safety and tolerability | Reference |
|-------|---------------------|------------------|-----------------------------|---------|-------------------------|-----------|
| P. rhamnosus strain GG | Probiotic, prebiotic | Remitted Mania | RCT (3 parallel arms: TAU, placebo, probiotics) | Improved YMRS scores, reduced side effects | | [87] |
| B. animalis strain Bb12 | Probiotic | Remitted Mania | RCT (3 parallel arms: TAU, placebo, probiotics) | Improved YMRS scores, reduced side effects | | [87] |
| Methylphenidate: 40 mg/d | Dopamine-reuptake inhibitor | Remitted Mania | OL (3 parallel arms: TAU, placebo, methylphenidate) | Improved YMRS scores, reduced side effects | | [90] |
| Memantine: 10 mg/d | NMDA receptor antagonist | Remitted Mania | RCT (3 parallel arms: TAU, placebo, memantine) | Improved YMRS scores, reduced side effects | | [113] |

**Key:**
- **Agent:** The agent under study.
- **Mechanism of action:** The mechanism by which the agent works.
- **Health condition:** The condition being treated.
- **Study design and drug doses:** The design of the study and the doses of the drugs used.
- **Results:** The results of the study.
- **Safety and tolerability:** The safety and tolerability profile of the agent.
- **Reference:** The reference for the study.

**Notes:**
- The table continues on the next page.
- The study for P. rhamnosus strain GG was a phase III RCT completed in 2020.
- The study for B. animalis strain Bb12 was a phase III RCT completed in 2021.
- The study for Methylphenidate was an open-label study completed in 2011.
- The study for Memantine was a phase III RCT completed in 2012.

**Additional Information:**
- KarXT is a combination of xanomeline, an experimental muscarinic M2 receptor cholinergic agonist, and tropismide chloride, an already marketed agent acting peripherally as a muscarinic cholinergic antagonist. Novelty features about KarXT mainly consist in targeting the cholinergic system without any anti-dopaminergic activity. This minimizes the risk for dopamine-system-related side-effects, common to many FGAs and SGAs. Regarding the putative use of central cholinergic agonists in BD, one should be aware of previous literature suggesting the presence of low levels of central acetylcholine in mania and high levels in depression [12]. While central cholinergic agonists are likely to reduce manic symptoms, the risk for counterpolar switch or the emergence of depressive symptoms should be taken in consideration and accurately monitored. KarXT completed a phase II trial in patients with Schizophrenia, showing statistically significant efficacy in reducing psychotic symptoms. However, adverse events related to cholinergic and anti-cholinergic activity (constipation, nausea, dry mouth, dyspepsia, and vomiting) were significantly more present in the active drug group compared with the placebo group [44]. Investigators conclude that larger and longer studies are needed to better specify the efficacy and safety profiles of KarXT. One open-label study to assess the long-term safety, tolerability and efficacy of KarXT in de novo subjects with Schizophrenia is ongoing [45] and expected to complete in July 2023.

Another non-dopaminergic agent under study in psychotic disorders is SEP-363856, a trace amine-associated receptor 1 (TAAR1) agonist and serotonin 5HT1A receptor agonist. It completed the phase II placebo-controlled RCT in 120 patients with an acute exacerbation of schizophrenia and proved to be effective in lowering psychotic symptoms and a good short-term safety/tolerability profile (more common adverse effects included somnolence and gastrointestinal symptoms but no differences in extrapyramidal and glucose-lipid metabolism were found between groups) [46]. SEP-363856 is currently under study in one placebo-controlled RCT to continue evaluating its efficacy and safety in patients with schizophrenia, followed by one open-label extension phase expected to be completed in June 2025 [47].

ROE689450 (or Ralmitaront) is another agent acting on TAAR1, with a partial agonist profile [48]. To our knowledge, phase II study results for Ralmitaront have not been published. One phase II trial of the efficacy and the safety of Ralmitaront vs placebo and risperidone in patients with an acute exacerbation of schizophrenia or schizoaffective disorder is currently ongoing, expected to complete in April 2023 [49].

Currently under-study antipsychotic agents with dopaminergic activity include Brilaroxazine (RP5063), F17464 and FK025SC, while Lumateperone (ITI-007) was finally approved by the FDA in December 2019 as a novel agent for the treatment of schizophrenia.

Lumateperone simultaneously modulates serotonin, dopamine and glutamate (SHT2A antagonist, D2 partial agonist, NMDA-GluN2B enhancer). In pre-approval clinical trials, it demonstrated efficacy in lowering psychotic symptoms during acute schizophrenia and a good short-term safety/tolerability profile with only somnolence/sedation indexes significantly higher than placebo [50]. Lumateperone’s pharmacodynamic profile suggested its hypothetical efficacy in bipolar depression and the results coming from the first trials tend to confirm the hypothesis [51–53]. No clinical trials of lumateperone in bipolar mania have been performed to our knowledge.

Brilaroxazine is a serotonin-dopamine modulator, structurally similar to aripiprazole, brexpiprazole, and cariprazine [54]. In a phase II double-blind, placebo and aripiprazole-controlled clinical trial, brilaroxazine demonstrated efficacy in reducing psychotic symptoms and signs of a good safety/tolerability profile: no significant changes in body weight, electrocardiogram, or incidence of orthostatic hypotension, decrease in blood glucose, lipid profiles, and prolactin levels. Aripiprazole was included only to demonstrate assay sensitivity and was not powered to show...
efficacy [55]. No ongoing clinical trials with brivaroxazine were found in the FDA and EMA’s registers.

F17464, a dopamine D3 antagonist-serotonin 5HT1A partial agonist, is under study as monotherapy for schizophrenia. It completed one phase II double-blind, placebo-controlled RCT where it proved to be effective in lowering Positive and Negative Syndrome Scale (PANSS) total, positive and general psychopathology subscores but not PANSS negative subscore, with a favorable safety profile [48, 56]. To the best of our knowledge, no clinical trials involving F17464 are ongoing.

AVN-211 is an experimental serotonin 5HT6R antagonist. In a pilot phase II, add-on, placebo-controlled RCT in schizophrenia patients, AVN-211 demonstrated efficacy in lowering PANSS positive and CGI-S scales [57]. It is currently under development according to producer Avineuro, but no ongoing trials were found in FDA or EMA’s registers.

Cannabidiol (CBD), an agent acting on a variety of neuronal receptors including CB1 (partial agonism) and serotonin 5HT1A (partial agonism), is currently under study for psychotic disorders in several clinical trials [58, 59]. Due to its receptor binding profile, it is supposed to show antipsychotic and proognitive properties [48]. In an exploratory, add-on, placebo-controlled clinical trial in patients with schizophrenia, CBD demonstrated efficacy in improving the Clinical Global Impression (CGI) score and in lowering PANSS positive subscore, but did not significantly differed from placebo in the Global Assessment of Functioning (GAF) and total, negative and general psychopathology PANSS scores [48]. Regarding the use of CBD in acute mania, just one small case series [60] exists, in which CBD showed no efficacy [61].

Nitroprusside over placebo in reducing psychotic symptoms [62]. However, three subsequent studies did not confirm these prior results [63-65].

Two phosphodiesterase (PDE) inhibitors are listed in Table 2. MK-8189 is a PDE10A inhibitor, expected to target both dopaminergic and glutamatergic activity in the striatum via cAMP, cGMP and phosphorylation-dependent mechanisms [48]. However, in one placebo and risperidone-controlled RCT with acutely ill schizophrenic patients, MK-8189 did not separate from placebo on efficacy outcome measures, while risperidone did [66]. Another similarly designed clinical trial with MK-8189 is actually ongoing and expected to complete in July 2022 [67].

BI 409306 is a PDE9A inhibitor whose putative mechanism involves glutamatergic regulation via cGMP-dependent mechanisms. This drug was tested in a phase II placebo-controlled clinical trial as add-on for cognitive symptoms in schizophrenia in which it did not separate from placebo in primary outcomes [68]. Now it is under study as an early intervention monotherapy for attenuated psychosis syndrome [69]. The study actually completed in April 2021, but results are still unpublished.

Pimavanserin is a serotonin 5HT2A inverse agonist, approved for the treatment of delusions and hallucinations in patients with Parkinson’s Disease. In one prior study pimavanserin was tested as augmentation therapy to risperidone for schizophrenia [70] and more recently as an add-on to background AP for treatment resistant schizophrenia [71]. While in the first study pimavanserin proved effective in augmenting risperidone’s antipsychotic potential with a good safety/tolerability profile, in the second one it did not reach statistical significance over placebo in lowering PANSS scores. Pimavanserin is currently under study as an add-on therapy for negative symptoms in schizophrenia [72]. The RCT is expected to be completed in March 2023.

Evenamide is an experimental agent with completed and ongoing phase II RCT in patients with Schizophrenia. Its mechanism of action includes voltage-gated sodium channel blockade and glutamate modulation [73]. In a phase II placebo-controlled RCT, Evenamide showed evidence of antipsychotic efficacy as an add-on to risperidone or aripiprazole, with no signs of dopaminergic or serotoninergic activity [74]. In March 2021, Evenamide completed another phase II, placebo-controlled RCT in patients with schizophrenia who were symptomatic on their SGA medication, but results of the study are still unknown [75]. Regarding a hypothetical treatment of bipolar mania with Evenamide, some promising features could be found in its mechanism of action (sodium channel blockade shared with MS like Divalproex, while adding glutamate regulation) and its demonstrated efficacy in lowering both PANSS total score and PANSS positive subscore. However, larger, longer and specifically designed RCT are needed to validate this hypothesis.

Non-Mood stabilizer/non-Antipsychotic emerging treatments

Multiple factors interact in the complex equation of the pathophysiology of a ME. As a consequence, beyond neurotransmission and signal transduction, also neuro-hormonal pathways, oxidative stress and changes in the immune system are considered as putative pharmacological targets for the treatment of a ME.

Tamoxifen and endoxifen. Tamoxifen is an estrogen antagonist whose mood-regulating properties are supposed to be mediated via phosphokinase C (PKC) inhibition [76]. A recent metaanalysis [77] found 5 RCT of tamoxifen in acute manic patients, 3 ass add-on and 2 as monotherapy. Results of the studies homogeneously indicate evidence of efficacy for tamoxifen over placebo in reducing manic symptoms. Endoxifen, an active metabolite of tamoxifen with a four-fold PKC inhibitory activity compared with tamoxifen, was recently tested in a phase III double-blind, divalproex-controlled RCT with acutely manic patients. The trial demonstrated efficacy of endoxifen in reducing manic symptoms and faster action as compared to divalproex with a good short-term adverse events profile [78, 79].

However, concerns about long-term side-effects limits the approval of these agents for clinical practice. Larger and longer RCT are needed to demonstrate long-term safety/tolerability reliability of PKC inhibitors for BD patients.

Antinflammatory and antioxidant drugs. Inflammation, oxidative stress, and mitochondrial dysfunction have been identified as key factors in the pathophysiology and neuroprogression of BD [11]. As a consequence, antinflammatory and antioxidant agents have been tested for efficacy in acute bipolar mania in recent years [80].

Regarding the use of anti-inflammatory drugs, Celecoxib was administered in two placebo-controlled RCT as add-on to Divalproex [81] or Lithium plus Risperidone [82] in patients with acute mania without psychotic symptoms. In both trials, celecoxib demonstrated significant efficacy in reducing manic symptoms compared to placebo. No ongoing clinical trials for treatment of bipolar mania with celecoxib or other antiinflammatory drugs were found in FDA or EMA registers.

N-acetylcysteine (NAC), a multi-target molecule with antioxidant properties, presented signs of efficacy in one post-hoc analysis with a subset of manic patients from a placebo-controlled RCT [83] with a small sample size (n = 15). Larger and specifically designed RCT are needed to validate hypothesis of efficacy.

Omega-3s are antiinflammatory molecules competing with arachidonic acid, thereby decreasing the production of proinflammatory eicosanoids. One small RCT (n = 15) evaluated the effects of add-on omega-3s in acute mania, finding no significant differences in manic symptoms compared to placebo [84].

Probiotics. Regulation of gut microbiota has been targeted in BD investigation with the aim of testing pro-cognitive and
mood-regulating effects of gut-brain signaling [12]. One placebo-controlled RCT was performed in patients discharged following hospitalization for acute mania [85]. The results showed efficacy for probiotics (Lactobacillus rhamnosus strain GG and Bifidobacterium animalis subsp. lactis strain Bb12) over placebo in delaying time to rehospitalization and reducing length of stay in psychiatric ward. Another probiotic intervention to prevent relapse following hospitalization for bipolar mania is currently ongoing and expected to complete in September 2021 [86].

Methylphenidate. Methylphenidate, a noradrenaline-dopamine reuptake inhibitor already approved in the US and EU for use in Attention-Deficit Hyperactivity Disorder and Narcolepsy, was recently tested in acute manic patients under the hypothesis that it could influence wakefulness with a mood-regulating outcome. The MEMAP study, a large multi-center placebo-controlled RCT concluded in September 2016, demonstrated a lack of efficacy for methylphenidate over placebo in acute mania [87].

Memantine. Lastly, Memantine is a glutamate NMDA receptor blocker, actually approved for use in moderate to severe Alzheimer’s disease but with a good amount of literature suggesting its use in other psychiatric disorders [88] and particularly bipolar disorder [89]. In a recent placebo-controlled RCT, conducted in Iran on a sample of 70 elderly patients with acute mania, memantine showed some efficacy as add-on to valproate in reducing manic symptoms and improving cognition over placebo [90].

DISCUSSION AND CONCLUSION
The treatment of mania still presents very important challenges, especially when the long-term is considered. Although the pharmacological armamentarium to treat this condition currently list a good number of drugs, the gap between evidence-based treatment and clinical practice is still considerable, and the majority of patients need combined pharmacological therapies and psychosocial interventions to achieve reasonable results in terms of clinical and functional outcomes.

Treatment of acute mania should be personalized in consideration of several clinical criteria, which include manic episode presentation features (psychotic, mixed, and anxious features), course specifiers (PP and rapid cycling), and patient factors (disease severity, comorbidities, treatment adherence, present and past treatment, and the stage of disease).

Another aspect to take into consideration is that for ethical reasons most of the evidence comes from studies where participants agree to participate and sign an informed consent to be enrolled in the study. As a consequence, they could present milder forms of mania in comparison with the patients commonly attended in clinical practice. For this reason, doses recommended in guidelines tend to be lower than those used in clinical practice and guidelines are also more supportive of monotherapy, while polytherapy is the rule in the real world.

Regarding the emerging approaches, the paucity of recent or ongoing trials specifically targeting the treatment of mania should be remarked. Experimental MSs we discussed in section 3.6.3 are worth mentioning, but none of them reach statistical significance of efficacy in acute mania and no ongoing trial is being conducted to replicate or modify those initial negative results. In addition, few expectations are linked to the effort of re-labelling existing APs for use in bipolar mania. Although probably influenced by some flaws in the design of the trial, Brexpiprazole recently failed to demonstrate efficacy in acute mania while for Iloperidone—which is marketed in the US but not in the European countries—results are awaited in May 2023. Among novel and experimental APs, the most promising agents under study for schizophrenia (e.g. KarXT, SEP-363856, RO6889450, ALKS3831, Evenamide) could be hypothetically considered to show benefits also for bipolar mania in consideration of their pharmacodynamic characteristic, antipsychotic efficacy and safety/tolerability profile. As we have already remarked, their main benefits in the field of psychopharmacotherapy are expected to come in terms of a better safety/tolerability profile than existing agents. As for safety/tolerability, regarding a putative use of these agents in the treatment of a ME, it may be again remarked that central cholinergic agonism exerted by KarXT should be accurately monitored for risk of counterpolar depressive switch. SEP-363856, RO6889450 might not present this risk. Lastly, ALKS3831 could ameliorate the already demonstrated efficacy of olanzapine in patients with BD, by improving its long-term metabolic safety/tolerability profile. Among non MS/non AP agents, PKC inhibitors (especially endoxifen) represent the class of drugs which proved to be capable of directly competing with approved agents in the treatment of mania, because demonstrated efficacy and a good short term safety/tolerability profile. However, concerns about their endocrinological activity make longer and larger RCT still necessary before considering their use in clinical practice. Other types of agents, like antiinflammatories/antioxidants or probiotics, demonstrated some level of efficacy as add-on to standard agents for reducing manic symptoms (celexob) or prolongate time to re-hospitalization after a manic episode (probiotics).

In addition, re-emerging approaches in the pharmacotherapy of BD—a topic which has gained attention in BD scientific literature in the last year [12, 91, 92]—should also be highlighted. The last few decades have seen a dramatic increase in available treatments for mania [93] and this has been associated with shifts in prescribing patterns with a reduction in the use of mood stabilizers and an increase in the use of antipsychotics [94]. However, despite the increase in available treatment options, there has also been a documented increase in dysfunction and disability in patients with bipolar illness [95]. This led some influencing authors in the field of BD research to advocate for the re-emergence of MSs’ prescription and to “Make Lithium Great Again!” [14]. While the validity of this argument is supported by several authors [91, 92], it is also important to intensify the efforts in the fields of experimental BD psychopharmacology and neurobiology in order to identify new treatment targets and pharmacological agents with better risk/benefits profiles.

Lastly, we would like to underline the importance of integrating pharmacological and non-pharmacological approaches in different stages of mania. A manic episode has to be seen as a severe episode of acute illness to be promptly treated, once its distinctive features are recognized, with the best personalized pharmacological approach, while keeping an eye on the long-term maintenance perspective. Once acute mania has remitted, prevention strategies such as behavioral and psychoeducation approaches should be implemented to lower the relapse risk [96]. These strategies include supporting continued treatment adherence, minimizing residual symptoms, early identifying signs of relapse, and promoting functional recovery [97–99].

Limitations
The main limitations of this work are connected with its strengths. They include the non-systematic nature of the review. However, the aim of this piece was to provide a critical overview and some practical indications about current and emerging approaches to mania, informed by our clinical experience. In this respect, our group has prolonged experience over three decades of treating large numbers of manic patients and we follow a large cohort of bipolar patients, which has been the source of significative, valuable knowledge. Finally, conflicts of interest of the authors are listed in the specific section.
56. Bitter L, Lieberman JA, Gaudoux F, Sokoloff P, Groc M, Chavda R, et al. Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia. Neuropsychopharmacology. 2019;44:1917–24.

57. Morozova MA, Lepilinka TA, Rupchev GE, Benashovy AG, Burmistrov DS, Partanin SS, et al. Add-on clinical effects of selective antagonist of SHT6 receptors AVN-211 (CID-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study. CNS Spectr. 2014;19:936–23.

58. ClinicalTrials.gov Identifier: NCT02088060.

59. ClinicalTrials.gov Identifier: NCT02504151.

60. Zuardi AW, Crippa JAS, Dursun SM, Morais SL, Vilela JAA, Sanches RF, et al. Cannabidiol as a treatment for mood disorders: a systematic review. Can J Psychiatry. 2020;65:213–27.

61. Hallack JCA, Maia-de-Oliveira JP, Arazo J, Evora PR, Zuardi AW, Crippa JA, et al. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial. JAMA Psychiatry. 2013;70:668–76.

62. Stone JM, Morrison PD, Koychev L, Gao F, Reilly TJ, Kolanko M, et al. The effect of sodium nitroprusside on psychotic symptoms and spatial working memory in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. Psychol Med. 2016;46:3433–50.

63. Wang X, Zhao J, Hu Y, Jiao Z, Lu Y, Ding M, et al. Sodium nitroprusside treatment for psychotic symptoms and cognitive deficits of schizophrenia: a randomized, double-blind, placebo-controlled trial. Psychiatry Res. 2018;269:271–7.

64. Brown HE, Freudenreich O, Fan X, Heard SO, Goff D, Petrides G, et al. Efficacy and tolerability of adjunctive intravenous sodium nitroprusside treatment for patients with schizophrenia: a randomised clinical trial. JAMA Psychiatry. 2019;76:691–9.

65. ClinicalTrials.gov Identifier: NCT03585338.

66. ClinicalTrials.gov Identifier: NCT04624243.

67. Brown D, Nakagome K, Cordes J, Bresser R, Grünke R, Keefe RSE, et al. Efficacy, safety, and tolerability of BI 409306, a novel phosphodiesterase 9 inhibitor, in cognitive impairment in schizophrenia: a randomized, double-blind, placebo-controlled, phase II trial. Schizophr Bull. 2019;45:3550–9.

68. Meltzer HY, Elkis H, Vanover K, Weiner DM, van Kammen DP, Peters P, et al. The sustained efficacy and safety of risperidone, 2 mg/day, but does not enhance efficacy of haloperidol, 2 mg/day: comparison with reference dose risperidone, 6 mg/day. Schizophr Res. 2012;141:144–52.

69. ClinicalTrials.gov Identifier: NCT03233007.

70. ClinicalTrials.gov Identifier: NCT04641119.

71. Saxena A, Scaini G, Bavarese DV, Leite C, Valvassoria SS, Carvalho AF, et al. Role of protein kinase C inhibitor in bipolar disorder: a review of the current literature. Mol Psychiatry. 2017;13:108–24.

72. Latean A, Poutoulis M, Khatibi-Moghadam H, Faridhosseini F, Farhoudi F, Askari-Noghani A, et al. Tamoxifen: a protein kinase C inhibitor to treat mania. A randomized, placebo-controlled pilot study. Br J Psychiatry. 2009;194:260–6.

73. ClinicalTrials.gov Identifier: NCT03970292.

74. Anand R, Borotalo M, Faravelli L. Glutamate modulation by evenamide, a Na+/channel blocker, may benefit treatment resistant schizophrenic (TRS) patients not responding to clozapine. Eur Neuropsychopharmacol. 2019;29:S540–1.

75. Anand R, Forrest EC, Hartman RD, Graham SM, Faravelli L, Evenamide, a voltage-gated sodium channel blocker in the treatment of schizophrenia: results from a placebo-controlled study. Eur Neuropsychopharmacol. 2017;27:594–8.

76. ClinicalTrials.gov Identifier: NCT0461119.

77. He H, Hu C, Ren Z, Bai L, Gao F, Liu J. Trends in the incidence and DALYs of bipolar disorder at global, regional, and national levels: results from the global burden of Disease Study 2017. J Clin Psychiatry. 2020;79:125–96.

78. Vieta E, Berk M, Schulze TG, Carvalho AF, Suppes T, Calabrese J, et al. Bipolar disorders. Nat Rev Dis Prim. 2018;4:18008.

79. Colom F, Vieta E, Sanchez, Moreno J, Palominio-Otiniano R, Reinares M, et al. Group psychoeducation for stabilised bipolar disorders: 5-year outcome of a randomised clinical trial. Br J Psychiatry. 2009;194:260–5.

80. Sole B, Jimenez E, Torrent C, Reinares M, Bonnin CDM, Torres I, et al. Cognitive impairment in bipolar disorder: treatment and prevention strategies. Int J Neuropsychopharmacol. 2017;20:670–80.

81. Vieta E, Torrent C. Functional remediation: the pathway from remission to recovery in bipolar disorder. World Psychiatry. 2016;15:288–9.

82. McDonnell D, Potkin SG, Simmons A, Jiang Y, DiPetrillo L, Silverman BE. F232. A phase 3 study to determine the antipsychotic efficacy and safety of ALKS 3831 in adult patients with acute exacerbation of schizophrenia. Schizophr Bull. 2018;44:S312–312.

83. Greenwood J, Acharya RB, Marcellus V, Rey JA. Luteotrophic peptide: a novel anti-psychotic for schizophrenia. Ann Pharmacother. 2021;55:98–104.

84. ClinicalTrials.gov Identifier: NCT02493736.

85. Bitter L, Lieberman JA, Florence F, Sokoloff P, Groc M, Chavda R, et al. Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia. Neuropsychopharmacology. 2019;44:1917–24.

86. Capuzzi E, Caldiroli A, Ciscato V, Russo S, Buoli M. Experimental serotonergic agents for the treatment of schizophrenia. J Exp Pharm. 2021;13:49.

87. Capuzzi E, Caldiroli A, Ciscato V, Russo S, Buoli M. Experimental serotonergic agents for the treatment of schizophrenia. J Exp Pharm. 2021;13:49.

88. Capuzzi E, Caldiroli A, Ciscato V, Russo S, Buoli M. Experimental serotonergic agents for the treatment of schizophrenia. J Exp Pharm. 2021;13:49.

89. Kulkarni J, Garland KA, Scaffidi A, Headey B, Anderson R, de Castella A, et al. A pilot study of hormone modulation as a new treatment for mania in women with bipolar disorder. Psychoneuroendocrinology. 2006;31:543–7.

90. Zarrate CA, Singh JB, Carlson PJ, Quiroz J, Jolovsky L, Luckenbaugh DA, et al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord. 2007;9:561–70.

91. Yildiz A, Guleyruz S, Ankerst DP, Ongur D, Renshaw PF. Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiat. 2008;65:55–263.
111. Amrollahi Z, Rezaei F, Salehi B, Modabbernia A-H, Maroufi A, Esfandiari G-R, et al. Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. J Affect Disord. 2011;129:327–31.

112. Kulkarni J, Berk M, Wang W, Mu L, Scarr E, Rheenen TEV, et al. A four week randomised control trial of adjunctive medroxyprogesterone and tamoxifen in women with mania. Psychoneuroendocrinology. 2014;43:52–61.

113. Keck PE Jr, Hsu HA, Papadakis K, Russo J Jr. Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation. Clin Neuropharmacol. 2009;32:199–204.

ACKNOWLEDGEMENTS
The Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2017 SGR 1365; 2017-SGR-1271), CIBERSAM, the CERCA Programme, the Spanish Ministry of Science and Innovation (CPI16/00018, CM19/00123, CD20/00177, PI15/00283, PI18/00805, PI18/01001), the “Pla estratègic de Recerca i Innovació en Salut 2016–2020” (SLT006/17/00357, SLT006/17/00345), the BITRECS project (Marie-Curie Grant No. 754550 and “La Caixa” Foundation LCF/PR/GN18/50310006).

AUTHOR CONTRIBUTIONS
GS, NV, IP, and EV designed the study. GS, NV, and IP managed the literature searches and critical review. GS wrote the first draft of the manuscript. IP, NV, and EV revised the first draft and added critical comments to guide the redaction of the final manuscript. All the authors approved the final manuscript.

COMPETING INTERESTS
GS has received financial support for CME activities from Lundbeck and reports no financial or other relationship relevant to the subject of this article. EV has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, Abbvie, Angelini, Dainippon Sumitomo Pharma, Gedeon Richter, Janssen, Lundbeck, Otsuka, Sage, Sanofi-Aventis, Takeda and reports no financial or other relationship relevant to the subject of this article.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to Eduard Vieta.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022